ATyr Pharma is working on Efzofitimod's clinical development, which is currently going through Phase I, Phase II, and Phase III of the clinical pathway. The likelihood of the drug moving from its current development stage to the next is fundamentally determined by the characteristics of the clinical trial as well as other aspects of the drug, regulations, and company.

GlobalData says that on December 22, 2022, the most recent event that changed Efzofitimod's likelihood of approval (LoA) and phase transition for pulmonary sarcoidosis occurred. This made it more likely that the drug would move on to the next phase of its clinical pathway and get final approval for this indication.

In their sarcoidosis market and Phase Transition Success Rate (PTSR) Report, GlobalData uses proprietary data and analytics to present a comprehensive picture of this assessment.

Overview of efzofitimod Efzofitimod (ATYR-1923) is being developed to treat rare pulmonary diseases with an immune component (RPIC). These diseases include interstitial lung diseases like chronic hypersensitivity pneumonitis and connective tissue diseases (CTD-ILD), pulmonary sarcoidosis, and coronavirus disease 2019 (COVID-19) with severe pneumonia. It is given through an intravenous line. Neuropilin-2 is the target of the potential drug. An immunoglobin Fc and the immuno-modulatory domain (iMod domain) of histidine aminoacyl tRNA synthetase (HARS) form the drug candidate.

For more insights on the sarcoidosis market, Download a Free Sample

An overview of aTyr Pharma: aTyr Pharma is a biotechnology company in the clinical stage. It is working on medicines that can be used to treat cancer and lung diseases in clinical trials. Based on the resokine pathway, its ATYR1923 is a clinical-stage product candidate that harnesses immune engagement in interstitial lung diseases and other immune-mediated diseases by binding to the neuropilin-2 receptor. It also focuses on tRNA synthetases' extracellular functionality research and development. Additionally, aTyr Pharma develops medications for metabolic disorders, neurodegenerative diseases, cancer, and inflammation. For its activities in research and development, the company works with research institutions. The US headquarters of Tyr Pharma are in San Diego, California.